Arrhythmias & electrophysiology
Mortality and readmissions after ventricular tachycardia ablation: An analysis of inpatient and outpatient state databases
Authors' conclusion
Mortality, long-term readmission, and recurrent VT remain high after VT ablation and include measurably important costs. Strategies to improve freedom from recurrent VT while managing comorbid conditions may serve as targets for improving the efficacy and cost-effectiveness of an important procedure applied to a vulnerable population.
Study context
- Population
- Patients undergoing inpatient and outpatient ventricular tachycardia (VT) ablation captured in the Healthcare Cost and Utilization Project data in Florida, Maryland, and New York from 2016 to 2020, with 1-year follow-up through 2021patients undergoing VT ablation
- Participants
- 3,899 patients
- Outcome
- Death during the initial episode of care
Main finding
As reported in the abstract
Died during the initial episode of care
2%
Further findings
1-year in-hospital mortality, all-cause readmission and recurrent VT readmission
- 1-year in-hospital mortality rate
- 6.8%
- All-cause readmission rate
- 43.4%
- Recurrent VT readmission rate
- 16.9%
- Broadly stable during the study period
Risk factors for in-hospital mortality and all-cause readmission within 1 year
- Coronary artery disease, chronic kidney disease, and heart failure independently associated with an increased risk
- P < 0.05
- Cox proportional hazards regression
Cause of readmission
- Recurrent VT was the most common cause of readmission
Costs
- All-cause readmissions increased costs by
- 55%
Original publication
Mortality and readmissions after ventricular tachycardia ablation: An analysis of inpatient and outpatient state databases. Heart Rhythm. Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →